Contravir

Canaccord Genuity acts as Sole Book-Running Manager for US$12 million Public Offering of Common Stock and Warrants for ContraVir Pharmaceuticals, Inc.

Canaccord Genuity is pleased to announce that on April 28, 2017, it completed a public offering of common stock and warrants to purchase common stock for ContraVir Pharmaceuticals, Inc. (Nasdaq:CTRV). The Company issued a total of 12,000,000 of its common stock and warrants to purchase 6,000,000 shares of its common stock at a combined offering price of US$1.00. Canaccord Genuity acted as sole book-running manager for the offering.

ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action. One compound, TXL™ (formerly CMX157), is a highly potent analog of the successful antiviral drug Viread® (tenofovir disoproxil fumerate), and is currently in Phase 2a of development. TXL™ has demonstrated the potential for low, once-daily dosing and decreased systemic exposure compared to tenofovir, thereby potentially reducing renal and bone side effects. CRV431, the other anti-HBV compound, is a next-generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. ContraVir is also developing Valnivudine, an orally available nucleoside analogue prodrug; Valnivudine is currently in Phase 3 for the treatment of herpes zoster. In addition to direct antiviral activity, Phase 2 data suggest that Valnivudine has the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).